MoFo represented Krystal Biotech, Inc. in its $143.75 million common stock offering at $65 per share. Goldman Sachs & Co. LLC, Cowen, and Evercore ISI acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering and Ladenburg Thalmann & Co. Inc. and SMBC Nikko acted as co-managers.
The deal team was led by John Campbell and included corporate associates John Hensley, Hillary Daniels, and Ken Taylor. Partner Jim Mullen and associate Bu Yin provided intellectual property counsel on the matter.
Krystal (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. MoFo has represented the company in corporate and intellectual property matters since its inception in 2016.
Read a news release relating to the offering.